John Blackwood is a Senior Research Scientist at Kymab responsible for the development of Kymab’s Bispecific Antibody Discovery Platform – IntelliSelect® Bispecific. This platform was exemplified through the development of KY1049, a fully-human Factor VIII-mimetic bispecific antibody which has entered formal development and is expected to enter clinical trials in 2021/22. Previous to Kymab, John was the lead scientist of three oncology antibody discovery programmes at IONTAS with Mike Dyson and John McCafferty. John received his Ph.D. from the University of Edinburgh, completing graduate work in Human genetics. This was followed by five-year postdoctoral position at the University of Cambridge, Biochemistry Department.